Avicena Group, Inc. develops pharmaceuticals and skin care products. It focuses on developing products based on its proprietary understanding of the regulation of cellular energy processes. The company's core technologies have broad applications in both pharmaceuticals and dermaceuticals. Avicena Group was founded by Rima Kaddurah-Daouk and M. Flint Beal in 1989 and is headquartered in Palo Alto, CA.

The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Alchemia Oncology Pty Ltd. provides oncology services. It specializes in the research, development and commercialization of pharmaceutical products for the treatment of cancer and other chronic diseases. The company develops various drugs based on Hyaluronic Acid Chemotransport Technology, a drug delivery platform based on hyaluronic acid and associated with chemotherapeutic agents. Alchemia Oncology was founded in 2012 and is headquartered in Clayton, Australia.

Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.

Xcellerex is a supplier of manufacturing technologies, developing and producing biomanufacturing systems and production-scale bioreactors. The biomanufacturing solutions transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. Its proprietary products offer significant advantages such as faster installation, lower capital investment, reduced risk of cross-contamination, and significantly increased flexibility compared with traditional manufacturing technologies. The company’s FlexFactory® is a completely modular and portable production train based on single-use technologies, advanced process automation, and compact cleanroom architecture. In 2002, the company was founded by Parrish M. Galliher inMarlborough, Massachusetts.

Metabasis is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs by applying its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' product pipeline represents candidates indicated for the treatment of metabolic diseases such as hyperlipidemia and diabetes, among others. Additionally, our pipeline includes drug candidates for the treatment of liver diseases such as hepatitis and primary liver cancer which the company plans to license to companies focused on these areas. All of our product candidates were developed internally using proprietary technologies including our NuMimetic and HepDirect technologies.

Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure.\nProtemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure.\nProtemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration.\nProtemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration.\nThe company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities.\nProtemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held.

Suzhou Xinhai Biotechnology Co., Ltd. is a Chinese private company located in Suzhou. The firm engages in research and experimental development on biotechnology.

Meditech was an Australian biotechnology company focusing on the development of carbohydrate-based therapeutics. The company's platform technology HyACT™ was a drug-delivery technology shown to be highly effective in treating a variety of cancer types. The company was Located in Victoria, Australia.

TNO is an independent research organization with approximately 3,000 employees. They believe in joint creation of value in social and economic terms. They focus on transitions or changes in five social themes: Industry, Healthy Living, Defense & Safety, Environment and Energy. Targeted innovation, which is what TNO stands. They develop knowledge not about knowledge, but about practical application.

GeneTrace Systems, Inc. is an American private company located in Alameda, CA, with domestic subsidiaries. The firm provides drug discovery and development services. It was founded by Joseph Monforte.

Mutabilis SA specializes in the discovery and development of anti-infective drugs. It focuses on novel therapeutic approaches for controlling severe and nosocomial infections. The firm offers antibacterial, vaccines, anti-infective agents, gram-positive & negative ant virulence lead series, specific antigens, and screening technologies for antibacterial and virulence targets. The company was founded in 2001 by Xavier Nassif and is headquartered in Romainville, France.

CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company operates through the following business divisions: Research and Development, New Drug Development division, New Drug Sales, Products Sales, and Real Estate Leasing. The Research and Development division provides analysis of clinical trials services. The New Drug Development division engages in the development of anti-cancer remedies, antibiotics, diabetes treatments, remedies for hypoxia diseases, obesity treatment medicines and others. Its products offered include Acelex. The company was founded by Cho Joong Myung and Ro Seong Gu on July 7, 2000 and is headquartered in Seongnam, South Korea.

Global Life Sciences Solutions USA LLC (doing business as Cytiva), part of Danaher Corp., is a company headquartered in Marlborough, MA, that manufactures therapeutics.\nThe company says this about itself: Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.